Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females

Pharmaceutical Research

Volumn 25, Issue 10, 2008, Pages 2327-2333

  Ashiru, Diane A I ^a   Patel, Rajesh ^b   Basit, Abdul W ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Efflux transporters; Excipients; Gastrointestinal transit; Gender; H2 receptor antagonists; Metabolism; Oral absorption; Permeability; Solubility

Indexed keywords

DRUG METABOLITE; EXCIPIENT; MACROGOL 400; RANITIDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG METABOLISM; DRUG SOLUBILITY; FEMALE; GASTROINTESTINAL TRANSIT; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; URINARY EXCRETION;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCIPIENTS; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; INTESTINAL ABSORPTION; MALE; POLYETHYLENE GLYCOLS; RANITIDINE; SEX FACTORS;

EID: 51649123932     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9635-y     Document Type: Article

References (47)

1. A. W. Basit J. M. Newton M. D. Short W. A. Waddington P. J. Ell L. F. Lacey 2001 The effect of polyethylene glycol 400 on gastrointestinal transit: Implications for the formulation of poorly-water soluble drugs Pharm. Res. 18 1146 1150
2. A. W. Basit F. Podczeck J. M. Newton W. A. Waddington P. J. Ell L. F. Lacey 2002 Influence of polyethylene glycol 400 on the gastrointestinal absorption of ranitidine Pharm. Res. 19 1368 1374
3. J. D. R. Schulze W. A. Waddington P. J. Ell G. E. Parsons M. D. Coffin A. W. Basit 2003 Concentration-dependent effects of polyethylene glycol 400 on gastrointestinal transit and drug absorption Pharm. Res. 20 1984 1988
4. V. Chadwick S. Phillips A. Hofmann 1977 Measurements of intestinal permeability using low molecular weight polyethylene glycols (PEG 400). I. Chemical analysis and biological properties of PEG 400 Gastroenterology 73 241 246
5. J. D. R. Schulze E. E. Peters A. W. Vickers J. S. Staton M. D. Coffin G. E. Parsons A. W. Basit 2005 Excipient effects on gastrointestinal transit and drug absorption in beagle dogs Int. J. Pharm. 300 67 75
6. J. D. Schulze D. A. Ashiru M. K. Khela D. F. Evans R. Patel G. E. Parsons M. D. Coffin A. W. Basit 2006 Impact of formulation excipients on human intestinal transit J. Pharm. Pharmacol. 58 821 815
7. G. L. Amidon H. Lennernas V. P. Shah J. R. Crison 1995 A theoretical basis for a biopharmaceutic drug classification-the correlation of in-vitro drug product dissolution and in-vivo bioavailability Pharm. Res. 12 413 420
8. M. L. Chen A. B. Straughn N. Sadrieh M. Meyer P. J. Faustino A. B. Ciavarella B. Meibohm C. R. Yates A. S. Hussain 2007 A modern view of excipient effects on bioequivalence: case study of sorbitol Pharm. Res. 24 73 80
9. K. M. Koch A. F. Parr J. J. Tomlinson E. P. Sandefer G. A. Digenis K. H. Donn J. R. Powell 1993 Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit-time Pharm. Res. 10 1027 1030
10. FDA. Department of Health and Human Services, Food and Drug Administration 1998 21 CFR parts 312 and 314. Docket No. 95N-0010, Investigational new drug applications and new drug applications Fed. Regist. 60 46794 46797
11. D. A. Ashiru R. Patel A. W. Basit 2007 Simple and universal HPLC-UV method to determine cimetidine, ranitidine, famotidine and nizatidine in urine: Application to the analysis of ranitidine and its metabolites in human volunteers J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 860 2 235 240
12. N. P. Chau P. Y. Zech N. Pozet A. Hadj-Aissa 1982 Ranitidine kinetics in normal subjects Clin. Pharmacol. Ther. 31 770 774
13. J. Flores Perez H. J. Olguin C. F. Perez G. P. Guille A. G. Perez A. C. Vieyra A. T. Lopez M. C. Portugal I. L. Asseff 2003 Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers Chronobio. Int. 20 485 494
14. C. K. Shim J. S. Hong 1989 Inter- and intrasubject variations of ranitidine pharmacokinetics after oral administration to normal male subjects J. Pharm. Sci. 78 990 994
15. F. AbadSantos A. J. Carcas P. Guerra C. Govantes C. Montuenga E. Gomez A. Fernandez J. Frias 1996 Evaluation of sex differences in the pharmacokinetics of ranitidine in humans J. Clin. Pharmacol. 36 748 751
16. D. L. Bourdet D. R. Thakker 2006 Saturable absorptive transport of the hydrophilic organic cation ranitidine in caco-2 cells: Role of pH-Dependent organic cation uptake system and p-glycoprotein Pharm. Res. 23 1165 1177
17. D. L. Bourdet G. M. Pollack D. R. Thakker 2006 Intestinal absorptive transport of the hydrophilic cation ranitidine: A kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in caco-2 cells Pharm. Res. 23 1178 1187
18. B. D. Rege L. X. Yu A. S. Hussain J. E. Polli 2001 Effect of common excipients on caco-2 transport of low-permeability drugs J. Pharm. Sci. 90 1776 1786
19. B. M. Johnson, W. N. Charman, and C. J. H. Porter. An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci. 4(Article 40):(2002).
20. Y. Urakami M. Okuda H. Saito K. Inui 2000 Hormonal regulation of organic cation transporter OCT2 expression in rat kidney FEBS Lett. 473 173 176
21. A. Collett N. B. Higgs E. Sims M. Rowland G. Warhurst 1999 Modulation of the permeability of H-2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2 J. Pharmacol. Exp. Ther. 288 171 178
22. P. Pavek G. Merino E. Wagenaar E. Bolscher M. Novotna J. W. Jonker A. H. Schinkel 2005 Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b) pyridine, and transport of cimetidine J. Pharmacol. Exp. Ther. 312 144 152
23. T. Yamagata H. Kusuhara M. Morishita K. Takayama H. Benameur Y. Sugiyama 2007 Effect of excipients on breast cancer resistance protein substrate uptake activity J. Control. Release 124 1 5
24. T. Yamagata H. Kusuhara M. Morishita K. Takayama H. Benameur Y. Sugiyama 2007 Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients Drug Metab. Dispos. 35 1142 1148
25. C. P. Zamber J. K. Lamba K. Yasuda J. Farnum K. Thummel J. D. Schuetz E. G. Schuetz 2003 Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine Pharmacogenetics 13 19 28
26. E. G. Schuetz K. N. Furuya J. D. Schuetz 1995 Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms J. Pharmacol. Exp. Ther. 275 1011 1018
27. G. Merino A. E. van Herwaarden E. Wagenaar J. W. Jonker A. H. Schinkel 2005 Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver Mol. Pharmacol. 67 1765 1771
28. C. Alonso M. Guilarte M. Vicario L. Ramos Z. Ramadan C. Martinez E. Saperas S. Kochhar J. Santos J. R. Malagelada 2007 Gender determines a differential epithelial response to stress in the healthy gut Gastroenterology 132 A334 A334
29. C. J. Roberts 1984 Clinical pharmacokinetics of ranitidine Clin. Pharmacokinet. 9 211 221
30. J. H. Lin 1991 Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations Clin. Pharmacokinet. 20 218 236
31. T. Gramatte E. el Desoky U. Klotz 1994 Site-dependent small intestinal absorption of ranitidine Eur. J. Clin. Pharmacol. 46 253 259
32. C. Martinez C. Albet J. A. Agundez E. Herrero J. A. Carrillo M. Marquez J. Benitez J. A. Ortiz 1999 Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists Clin. Pharmacol. Ther. 65 369 376
33. A. M. van Hecken T. B. Tjandramaga A. Mullie R. Verbesselt P. J. de Schepper 1982 Ranitidine: single dose pharmacokinetics and absolute bioavailability in man Br. J. Clin. Pharmacol. 14 195 200
34. P. F. Carey L. E. Martin P. E. Owen 1981 Determination of ranitidine and its metabolites in human urine by reversed-phase ion-pair high-performance liquid chromatography J. Chromatogr. B 225 161 168
35. R. Sadik H. Abrahamsson P. O. Stotzer 2003 Gender differences in gut transit shown with a newly developed radiological procedure Scand. J. Gastroenterol. 38 36 42
36. J. Graff K. Brinch J. L. Madsen 2001 Gastrointestinal mean transit times in young and middle-aged healthy subjects Clin. Physiol. 21 253 259
37. L. Degen C. Petrig D. Studer S. Schroller C. Beglinger 2005 Effect of tegaserod on gut transit in male and female subjects Neurogastroenterol. Motil. 17 821 826
38. F. Gotch J. Nadell I. S. Edelman 1957 Gastrointestinal water and electrolytes. IV. The equilibration of deuterium oxide (D2O) in gastrointestinal contents and the proportion of total body water (T.B.W.) in the gastrointestinal tract J. Clin. Invest. 36 289 296
39. M. L. Chen 2005 Confounding factors for sex differences in pharmacokinetics and pharmacodynamics: Focus on dosing regimen, dosage form, and formulation Clin. Pharmacol. Ther. 78 322 329
40. B. Meibohm I. Beierle H. Derendorf 2002 How important are gender differences in pharmacokinetics? Clin. Pharmacokinet. 41 329 342
41. J. B. Schwartz 2003 The influence of sex on pharmacokinetics Clin. Pharmacokinet. 42 107 121
42. F. Franconi S. Brunelleschi L. Steardo V. Cuomo 2007 Gender differences in drug responses Pharmacol. Res. 55 81 95
43. M. E. Krecic-Shepard C. R. Barnas J. Slimko M. P. Jones J. B. Schwartz 2000 Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans J. Clin. Pharmacol. 40 219 230
44. A. B. Luzier A. Killian J. H. Wilton M. F. Wilson A. Forrest D. J. Kazierad 1999 Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers Clin. Pharmacol. Ther. 66 594 601
45. U. K. Walle T. C. Fagan M. J. Topmiller E. C. Conradi T. Walle 1994 The influence of gender and sex steroid hormones on the plasma binding of propranolol enantiomers Br. J. Clin. Pharmacol. 37 21 25
46. D. A. Gilmore J. Gal J. G. Gerber A. S. Nies 1992 Age and gender influence the stereoselective pharmacokinetics of propranolol J. Pharmacol. Exp. Ther. 261 1181 1186
47. S. H. Preskorn 1997 Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism Clin. Pharmacokinet. 32 Suppl 1 1 21